Uticaj težine hronične opstruktivne bolesti pluća na sistolnu funkciju desne komore

Marija Marinković (1*), Hristina Jovanović (2), Nemanja Nikolić (3), Tamara Nikolić (2), Marija Topalović (1), Borislav Božanić (1), Velimir Perić (4), Nikola Petković (5), Jasmina Jocić (6), Milica Ćosić (7), Tomislav Kostić (8), Tatjana Pejčić (1)

1.   Klinika za plućne bolesti, Univerzitetski Klinički Centar Niš, Niš, Srbija

2.   Univerzitet u Nišu, Medicinski fakultet, Niš, Srbija

3.   Poliklinika dr Nikolić, Niš, Srbija

4.   Klinika za kardiohirurgiju, Univerzitetski Klinički Centar Niš, Niš, Srbija

5.   Klinika za plastičnu i rekonstruktivnu hirurgiju, Univerzitetski Klinički Centar Niš,Niš,Srbija

6.   Institut za lečenje i rehabilitaciju Niška banja

7.   Klinika za Infektivne bolesti, Univerzitetski Klinički Centar Niš, Niš, Srbija

8.   Klinika za kardiologiju, Univerzitetski Klinički Centar Niš, Niš, Srbija

Kontakt: Marija Marinković

Jeronimova 19/10, 18000 Niš, Srbija

E-mail: drmarijamarinkovic2@gmail.com

Tel: 0691761775

Effect of severity of chronic obstructive pulmonary disease on the right ventricular systolic function

Marija Marinkovic (1*), Hristina Jovanovic (2), Nemanja Nikolic (3), Tamara Nikolic (2), Marija Topalovic (1), Borislav Bozanic (1), Velimir Peric (4), Nikola Petkovic (5), Jasmina Jocic (6), Milica Ćosic (7) Tomislav Kostic (8), Tatjana Pejcic (1)

1. Clinic for pulmonary diseases, University Clinical Center Nis, Nis, Serbia

2. University of Nis, Faculty of Medicine, Nis, Serbia

3. Dr. Nikolić Polyclinic, Nis, Serbia

4. Clinic for Cardiac Surgery, University Clinical Center Nis, Nis, Serbia

5. Clinic for Plastic and Reconstructive Surgery, University Clinical Center Nis, Nis, Serbia

6. Institute for treatment and rehabilitation Niska spa

7. Clinic for Infective diseases, University Clinical Center Nis, Nis, Serbia

8. Clinic for cardiology, University Clinical Center Nis, Nis, Serbia

Contact: Marija Marinković

Jeronimova Street, No 19/10, 18000 Nis, Serbia

E-mail: drmarijamarinkovic2@gmail.com

Phone: 0691761775

Uticaj težine hronične opstruktivne bolesti pluća na sistolnu funkciju desne komore

Prema navodima Svetske zdravstvene organizacije, najčešća komplikacija HOBP je hronično plućno srce (cor pulmonale chronicum) i predstavlja hipertrofiju miokarda desne komore, dilataciju i insuficijenciju desne komore koja nastaje kao posledica promena funkcije/strukture pluća, u odsustvu bolesti levog srca. Zlatni standard u otkrivanju promena funkcije desnog srca kod pacijenata obolelih od HOBP je ehokardiografski pregled. Glavni cilj ovog istraživanja je da se utvrdi uticaj stepena težine HOBP na vrednosti parametra sistolne funkcije desne komore, a sporedni cilj ovog istraživanja je utvrditi učestalost trikuspitalne regrugitacije u odnosu na stepen HOBP. Za detaljnu procenu sistolne funkcije desne komore koje su od značaja za ciljeve studije urađeni su sledeći parametri: procentualna frakcija promene povrsine desne komore (FAC), trikuspidna regurgitacija (TR) i amplituda sistolne pokretljivosti trikuspidnog prstena TAPSE (mm) kod 44 pacijenata obolelih od HOBP koji su bili podeljeni u 4 grupe prema GOLD kriterijumima. Nije bilo statistički značajne razlike među grupama za antropometrijske pokazatelje i vrednosti FEV1 (%) (p>0.05). Kruskal-Wallisovim testom uočava se da su vrednosti TAPSE indexa i FAC-a značajno veće kod pacijenata sa teškom i veoma teškom HOBP (p<0.05). Za učestalost TR statistički postoji značajna razlika za učestalost TR kod blage u odnosu na umerenu i tešku HOBP, kao i između umerene i teške bolesti HOBP (p<0.05). Rezultati našeg istraživanja pokazuju da su ehokardiografski parametri desne komore kao što su TAPSE, FAC i TR veoma značajni za procenu njene sistolne funkcije i da srazmerno ove vrednosti opadaju sa progresijom bolesti HOBP.

Ključne reči: HOBP, TAPSE index, FAC, TR

Effect of severity of chronic obstructive pulmonary disease on the right ventricular systolic function

According to the World Health Organization, the most common complication of COPD is chronic pulmonary heart disease (cor pulmonale chronicum) and represents myocardial hypertrophy of the right ventricle, dilatation and insufficiency of the right ventricle that occurs as a result of changes in lung function/structure, in the absence of left heart disease. The gold standard in detecting changes in right heart function in patients with COPD is an echocardiographic examination. The main goal of this research is to determine the influence of the severity of COPD on the values of the right ventricular systolic function parameter, and the secondary goal of this research is to determine the frequency of tricuspid regurgitation in relation to the degree of COPD. For a detailed assessment of the systolic function of the right ventricle, which are important for the objectives of the study, the following parameters were performed: the percentage fraction of the change in the area of the right ventricle (FAC) and the amplitude of the systolic mobility of the tricuspid ring TAPSE (mm) in 44 patients with COPD which were divided into 4 groups according to the GOLD criteria. There was no statistically significant difference between the groups for anthropometric indicators and FEV1 values (%) ($p>0.05$).

The Kruskal-Wallis test shows that the TAPSE index and FAC values are significantly higher in patients with severe and very severe COPD ($p<0.05$). The results of our research show that echocardiographic parameters of the right ventricle such as TAPSE and FAC are very important for the assessment of its systolic function and that these values decrease proportionally with the progression of the COPD disease.

Key words: COPD, TAPSE index, FAC

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is progressive and is the result of airway inflammation and remodeling associated with parenchymal destruction and the development of emphysema (1). The leading risk factor for the development of COPD is the consumption of cigarettes, and in areas of air pollution, the disease has an endemic character. It occurs mainly in people over 40 years of age. Patients have symptoms more often in the morning (productive cough, dyspnea) (2).

It is estimated that 210 million people in the world suffer from COPD and that about 3 million people die from this disease every year. It is the 3rd leading cause of death in the world, and over 500,000 patients have been registered in the Republic of Serbia (2). The diagnosis of COPD is determined by a clinical examination based on symptoms, auscultatory findings and diagnostic procedures - spirometry and a post-bronchodilator test that indicates the relationship FEV1/FVC < 0.70%. Based on the GOLD classification, it is divided into mild, moderate, severe and very severe COPD (2).

COPD is associated with significant extrapulmonary (systemic) effects, among which cardiac complications are the most common. Diseases of CVD and COPD are linked by: a large number of common risk factors (eg tobacco smoke in coronary disease and COPD), heart dysfunction as the last change in lung functions (primary pulmonary hypertension, increase in intrathoracic pressure), high level of inflammatory proteins in the blood (CRP -a) (3), disturbance of pulmonary ventilation (FEV1 and FVC) and disturbance of blood gases indicating the development of hypoxia and respiratory acidosis (4). Endogenous metabolic disorders and failure of neural compensatory mechanisms (5).

By increasing the resistance in the pulmonary blood vessels, changes occur in the pulmonary blood vessels and ventricles, which can lead to the development of pulmonary hypertension and chronic pulmonary heart disease, right systolic dysfunction and left ventricular diastolic dysfunction (6). According to the World Health Organization, the most common complication of COPD is chronic pulmonary heart disease (cor pulmonale chronicum) and represents myocardial hypertrophy of the

right ventricle, dilatation and insufficiency of the right ventricle that occurs as a result of changes in lung function/structure, in the absence of left heart disease (7).

The gold standard in detecting changes in right heart function in patients with COPD is an echocardiographic examination. Echocardiographic characteristics of chronic pulmonary heart disease: enlarged right atrium and right ventricle, right ventricular hypertrophy, paradoxical septum movements that occur as a result of loading the right ventricle with increased pressure in the pulmonary circulation (8,9). To assess the function of the circumferential myocardial fibers of the right ventricle, FAC is determined, a parameter that indicates the percentage change in the area of the right ventricle in systole compared to diastole and directly correlates with the ejection fraction of the right ventricle obtained by magnetic resonance imaging.

Left ventricular dysfunction parameter values in COPD patients are often the subject of studies by pulmonologists and cardiologists around the world, and pulmonary hypertension is often investigated. However, parameters of right ventricular dysfunction are rarely examined.

THE AIM

The main goal of this research is to determine the influence of the severity of COPD on the values of the right ventricular systolic function parameter, and the secondary goal of this research is to determine the frequency of tricuspid regurgitation in relation to the degree of COPD.

Exeminees

This prospective study included 44 patients with chronic obstructive pulmonary disease. The research was conducted at the Pulmonary Clinic of the University Clinical Center in Niš in the period from January 2021 to January 2022. Patients were included in the research during regular examinations at the Clinic for Pulmonary Diseases of the University Hospital Niš. During the examinationg, prior to hospitalization or previous outpatient examinations, patients were proven to suffer from COPD according to the standardized GOLD criteria. Data on the clinical picture of each patient were obtained through anamnesis and clinical examination. Among the pulmonological diagnostic methods, spirometry, bronchodilator test and blood gas analysis were performed. Of the cardiological diagnostic methods, blood pressure was measured with a sphingometer, a standard

12-channel electrocardiogram (ECG) and an echocardiographic examination were performed. All patients had their body weight and body height measured.

The criteria for inclusion in the study were: chronic obstructive pulmonary disease proven by GOLD criteria, stable phase of chronic obstructive pulmonary disease, preserved left ventricular function (LVEF > 50%).

Criteria for excluding patients from the study: other lung diseases (interstitial lung diseases, pulmonary thromboembolism, lung cancer), coronary disease and recent acute myocardial infarction, hemodynamically significant heart defects, previous cardiac surgery, diabetes mellitus type I and type II, chronic renal insufficiency, reduced left ventricular function (EF < 55%), signs of left ventricular hypertrophy on ECG findings.

At the end of the regular checkup, the patients received information about the purpose and protocol of the research and signed their consent to participate in the research. Only doctors/researchers have access to data from the medical history and the results obtained from diagnostic procedures, and no information other than gender and age will be published or used for illegal purposes.

Pulmonological diagnostic methods and blood gas analysis

Arterial blood gas analyzes were measured using the micromethod, by taking blood samples from the radial artery and measuring them using an AVL99 gas analyzer from the company AVL Gratz, Austria. Values of PaO_2, $PaCO_2$ (10) were evaluated. The bronchodilator test was performed according to the recommendations of the European Respiratory Society ERS/ATS (11). Spirometric tests were performed with a pneumotachograph of the company Erich Jaeger, Würzburg, model Masterlab. The results are presented in absolute measurement units and in relative measurement units (%). The spirometric measurements we used in the diagnosis of COPD are: FVC (forced vital capacity): the maximum volume of air during forced expiration, FEV1 (forced expiratory volume in the first second): the volume of air that is blown out in the first second of maximum expiration after a full inhalation. It is a measure of lung emptying rate, FEV1/FVC: FEV1, expressed as a percentage of FVC, provides a clinically useful index of airflow limitation.

In patients with a post-bronchodilator FEV1/FVC value < 70%, numbers from 1 to 4 according to the GOLD criteria provide information on the degree of reduction in the percentage value of FEV1 and limited airflow in the airways. According to the GOLD criteria, COPD is classified as a disease with mild, severe, severe and very severe ventilation disorder. (12).

Cardiological diagnostic methods - Echocardiography

Standard two-dimensional echocardiography (performed on a GE Vivid 4 machine using a 2.5 MHz probe) includes a longitudinal parasternal (PLAX) (PSAX), parasternal transverse, apical, and subcostal echocardiographic window. Two-dimensional (2D), M-mode, continuous (CW), pulsed (PW) color doppler and tissue doppler were used.

For a detailed assessment of the systolic function of the right ventricle, which are important for the study objectives, the following parameters were performed: percentage fraction of change in the area of the right ventricle (FAC) and the amplitude of the systolic mobility of the tricuspid ring TAPSE (mm).

Assessments of all parameters were determined by an echocardiographer according to echocardiographic guidelines (13,14,15). TAPSE characterizes the function of longitudinal right ventricular myocardial fibers and is measured in a four-chamber apical section by placing an M-mode cursor through the lateral tricuspid annulus, (normal values >15mm). FAC values are obtained by measuring the area of the right ventricle in diastole and in systole using the formula Ad-As/Ad (Ad – area of the right ventricle in diastole, As – area of the right ventricle in systole) expressed as a percentage, (normal value >35%).

Statistical analyses

In all tests, the obtained level of statistical significance was expressed, and a value of $p < 0.05$ or $p < 0.01$ was considered statistically significant, depending on the obtained results of the corresponding test. The collected data were entered into a specially created database on a personal computer, and statistical processing was done with the help of the Statistical Package for the Social Sciences (SPSS) for Windows program. The results are presented in tables and graphs with a textual commentary.

RESULTS

The research included 44 examinees suffering from COPD (28 males and 16 females). The examinees were divided into four groups according to the severity of the disease previously determined by the GOLD criteria. There were 11 patients in each group.

The patients were from 50 to 80 years old. The average age of patients who made up the first group of subjects with a mild form of COPD was 58.70 ± 7.9, in the group of patients with deceased COPD 57.80 ± 7.5, in the group with severe COPD 61.54 ± 6.7, while in the group the average age of patients with very severe COPD was 60.56 ± 4.4. There was no statistically significant difference in age distribution between the groups.

The anthropometric indicators of the patients are entered in Table 1 and Table 2. Table 1 shows the average values for the body mass and body height of the patients by group, while the calculated values for the body surface area and BMI are entered in Table 2. There was no significant difference for any the value of anthropometric indicators among the groups of examinees (p>0.05).

Table 1. Anthropometric indicators: values of body mass (kg) and body height (cm)

STADIUM	N	TM			TV		
		X±SD	Minimum	Maximum	X±SD	Minimum	Maximum
I	11	78,73 ± 17,86	54	114	175,4 ± 9,3	158	186
II	11	78,43 ±18,4	52	119	174,05 ±6,6	158	185
III	11	69,8 ± 12,8	42	96	173,2 ± 5,8	160	189
IV	11	68,3 ± 13,4	50	109	172,55 ± 7,4	159	186

Table 2. Anthropometric indicators: body surface area (m2) and BMI (kg/m2)

STADIUM	N	TP			BMI		
		X±SD	Minimum	Maximum	X±SD	Minimum	Maximum
I	11	1.99 ± 0,28	1,61	2,80	25,71 ± 4,3	19,36	33,24
II	11	1.95 ± 0,20	1,61	2,25	26,33 ± 6,5	17,70	41,52
III	11	1.85 ± 0,16	1,45	2,10	23,55 ± 4,1	14,52	33,06
IV	11	1,82 ± 0,15	1,50	2,30	23,3 ± 4,8	15,82	36,32

FEV1 values (%) obtained by spirometry are shown in Table 3. The Kruskal-Wails test proved that there is a significant difference for FEV1 among all groups (p=0.05), except for FEV1 values between the third and fourth group.

Table 3. FEV1 values (%)

STADIUM	N	X±SD	Minimum	Maximum
I	11	92,87± 10,0	80,00	113,00
II	11	61,8 ± 7,6	50,00	78,2
III	11	32,32 ± 7,2	21,49	47,8
IV	11	27,13 ± 5,8	17,70	41,0

Out of 44 patients, 7 (15.8%) had TAPSE ≤ 15mm. In the group of patients with mild or moderate COPD, there were no patients who had TAPSE ≤ 15 mm, the prevalence in severe disease is 26.67% (3 patients) and in very severe 36.67% (4 patients). There are statistically significant differences in prevalence between groups (p<0.01). With the progression of the disease, the systolic function of the myocardium of the right ventricle decreases significantly. In terminal illness, the prevalence of decreased TAPSE, which indicates decreased systolic function of the right ventricle, is the highest.

Table 4 lists the values of the TAPSE index by group. By comparing the values of the TAPSE index using the Kruskal-Wallis test, a statistically significant difference can be observed between the second and third groups of patients, the first and fourth, as well as the second and fourth

(p<0.05).

Table 4. TAPSE index values

STADIUM	N	X±SD
I	11	$2,05 \pm 0,30$
II	11	$2,09 \pm 0,29$
III	11	$1,81 \pm 0,34$
IV	11	$1,72 \pm 0,32$

The values for FAC are shown in Table 5. The Kruskal-Wallis test proved that FAC values were statistically significantly lower in patients with severe and very severe COPD, compared to values in patients with mild or moderate form of COPD (p<0.05).

Tabela 5. FAC values (mm)

STADIUM	N	X±SD
I	11	$40,05 \pm 0,30$
II	11	$40,09 \pm 0,29$
III	11	$35,01 \pm 0,34$
IV	11	$34,02 \pm 0,32$

Figure 1. Spirometric classification of COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for the year 2022.

STADIUM	DISTURBANCE OF VENTILATION	FEV1 (%)
GOLD 1	mild	≥80
GOLD 2	moderate	50-79
GOLD 3	severe	30-49
GOLD 4	very severe	<30

DISCUSSION

The function of the right ventricle represents an important component of the entire cardiac function and is of prognostic and predictive significance for the origin, development and outcome of various cardiovascular diseases, non-ischemic cardiomyopathies and pulmonary hypertension (16). Changes in the pulmonary circulation often lead to diseases of the cardiovascular system, especially to the development of secondary pulmonary hypertension due to increased resistance in the pulmonary blood vessels. As a result of remodeling of the right heart, insufficiency and dilatation of the right ventricle occurs over time, which in the absence of left heart disease is called cor pulmonale chronicum and is the most common complication of COPD (6,7).

By echocardiographic examination in patients with COPD, we can determine numerous parameters of the right heart cavities, which are used to evaluate the function of the right ventricle. In our research, the following parameters were used for a detailed assessment of the systolic function of the right ventricle: the amplitude of the systolic mobility of the tricuspid ring TAPSE (mm), the percentage fraction of the change in the area of the right ventricle (FAC) and tricuspid regurgitation (TR).

Kaul et al first confirmed the use of TAPSE as a parameter of right ventricular systolic function in 1984, when a strong correlation of this parameter with right ventricular ejection fraction was established by radionucleotide angiography. TAPSE is known as tricuspid ring motion and represents the longitudinal function of the right ventricular myocardium (17). A decrease in TAPSE values in patients with COPD has been described in various studies, but the mechanism of this connection is complex and not fully elucidated (18).

According to the results of our study, the TAPSE value significantly decreases with the progression of COPD. In severe COPD, the prevalence of reduced TAPSE, which indicates reduced systolic function, is the highest (p<0.01). Similar to our results, Vizza and colleagues described in 1998 that the drop in the ejection fraction of the right ventricle is most pronounced in patients in the terminal phase of COPD (19). In other studies, a reduced TAPSE was described in patients with COPD, only if these patients had also developed pulmonary hypertension (20). Reduced right ventricular ejection fraction assessed by TAPSE

is a predictor of mortality in all patients with heart failure, regardless of the presence of COPD in the patient (21).

According to the results of our study, the TAPSE value significantly decreases with the progression of COPD. In severe COPD, the prevalence of reduced TAPSE, which indicates reduced systolic function, is the highest ($p < 0.01$). Similar to our results, Vizza and colleagues described in 1998 that the drop in the ejection fraction of the right ventricle is most pronounced in patients in the terminal phase of COPD (19). In other studies, a reduced TAPSE was described in patients with COPD, only if these patients had also developed pulmonary hypertension (20). Reduced right ventricular ejection fraction assessed by TAPSE is a predictor of mortality in all patients with heart failure, regardless of the presence of COPD in the patient (21).

In 2020 and 2021, the TAPSE was used as an indicator of mortality in patients with COVID-19 in several studies, the results of which were included in a systematic review of researchers from Indonesia. According to the results, for every 1 mm of TAPSE decrease, the mortality rate of patients with COVID19 increases by approximately 20%. (22). TAPSE, as a significant parameter of right ventricular systolic dysfunction, can be used to differentiate sub-massive from non-massive pulmonary embolism (23).

Measurement of right ventricular ejection fraction is an important indicator of morbidity and mortality in patients with COPD (24,25). In addition to TAPSE, another parameter strongly correlates with EFRV, which is the percentage fraction of change in right ventricular area (FAC). FAC values are obtained by measuring the area of the right ventricle in diastole and in systole using the formula Ad-As/Ad (Ad – area of the right ventricle in diastole, As – area of the right ventricle in systole) expressed as a percentage. FAC less than 35% indicates right ventricular systolic dysfunction. FAC% correlates with right ventricular ejection fraction (RVEF) measured by magnetic resonance imaging (MRI) (26).

Numerous studies have shown that a decrease in TAPSE is accompanied by a decrease in FAC (14,27,28,29). In line with those results, ours show the same observations. FAC values decrease with the progression of COPD, and the lowest percentage values are found in patients with stage IV COPD ($p < 0.01$). Gosh at al. proved that the reduction of FAC

according to the stages of COPD is highly proportional (30). In a study by Chen et al, it was shown that FAC and TAPSE were significantly lower in patients with COPD compared to healthy individuals. Also, it has been proven that in addition to these parameters TR ,tricuspid E∕A ,E∕e, RVMPI, , RVTD and TRPG can be used to assess change of right ventricular function in early stages (31). According to the results of the study by Ghio et al., FAC is a less reproducible measure of reduced right ventricular systolic function than TAPSE (24). These observations are probably due to the fact that the FAC measure is much more variable because it is mathematically determined on the basis of echocardiographic measures of the systolic and diastolic area of the right ventricle.

CONCLUSION

COPD as a disease is accompanied by a large number of extrapulmonary manifestations, among which the most frequent are cardiac manifestations. The results of our research show that echocardiographic parameters of the right ventricle such as TAPSE, FAC and TR are very important for the assessment of its systolic function and that these values decrease proportionally with the progression of the COPD disease. Based on the above results and by comparing the results of other studies, it can be concluded that an echocardiographic examination is necessary for monitoring the cardiac function of these patients and that it is necessary to introduce it routinely for COPD patients in order to reduce the load on the heart, especially the right one, keep it under control and improve the quality of life with an appropriate therapy.

LITERATURE

1. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165–1185

2. Nacionalni vodič dobre kliničke prakse : Hronična opstruktivna bolest pluća. Institut za javno zdravlje "Dr Milan Jovanović Batut". Beograd, 2013.

3. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 250–255.

4. Schünemann HJ, Dorn J, Grant BJ, Winkelstein W Jr, Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 2000; 118(3): 656-664.

5. Foster TS, Miller JD, Marton JP, Caloyeras JP, Russell MW, Menzin J. Assessment of the economic burden of COPD in the US: a review and synthesis of the literature. COPD 2006; 3: 211–218.

6. Zile MR, Brutsaert DL. New Concepts in Diastolic Dysfunction and Diastolic Heart Failure: Part I, Diagnosis, Prognosis, and Measurements of Diastolic Function. Circulation, 2002; 105: 1387–1393.

7.Chronic respiratory diseases. WHO, 2022. Pristupljeno 13.07.2022. Dostupno na : https://www.who.int/health-topics/chronic-respiratory-diseases#tab=tab_3

8. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009 Oct ;30(20): 2493-537.

9. Cuttica MJ, Shah SJ, Rosenberg SR, Orr R, Beussink L. et al. Right Heart Structural Changes Are Independently Associated with Exercise Capacity in Non-Severe COPD. PLoS ONE 2011; 6(12): e29069

10. Rennard SI, Drummond MB. Early chronic obstructive pulmonary disease: definition, assessment, and prevention. Lancet 2015 May 2; 385(9979): 1778-1788.

11. Brusasco V, Crapo R, Viegi G. Coming together: the ATS/ERS consensus on clinical pulmonary function testing. Eur Respir J 2005; 26(1): 1–2.

12. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease report; 2022.

13. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010 Jul; 23(7): 685-713.

14. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ; Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005 Dec; 18(12):1440-1463.

15. Quiñones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA; Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr. 2002 Feb; 15(2): 167-184.

16. Juillière Y, Barbier G, Feldmann L, Grentzinger A, Danchin N, Cherrier F. Additional predictive value of both left and right ventricular ejection fractions on long-term survival in idiopathic dilated cardiomyopathy. Eur Heart J 1997; 18(2): 276-280.

17. Kaul S, Tei C, Hopkins JM, Shah PM. Assessment of right ventricular function using two-dimensional echocardiography. Am Heart J 1984; 107(3): 526-531.

18. O.C. Burghuber, Right ventricular contractility is preserved and preload increased in patients with chronic obstructive pulmonary disease and pulmonary artery hypertension, in: V. Jezek, M. Morpurgo, R. Tramarin (Eds.), Right Ventricular Hypertrophy and Function in Chronic Lung Disease, Springer-Verlag, Berlin 1992, pp. 135–141

19. Vizza CD, Lynch JP, Ochoa LL, Richardson G, Trulock EP. Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest 1998; 113(3): 576-583.

20. Najafian J, Taheri S, Mahaki B, Molavi S, Alami S, Khalesi S, Salehi A. Comparing right ventricular function and pulmonary artery pressure before and shortly after hemodialysis in patients with end-stage renal disease. Adv Biomed Res 2015; 4:197.

21. Kjaergaard J, Akkan D, Iversen KK, et al. Right ventricular dysfunction as an independent predictor of short- and long-term mortality in patients with heart failure. Eur J of Heart Fail 2007; 9(6-7): 610-616.

22. Martha J W, Pranata R , Wibowo A, Lim MA. Tricuspid annular plane systolic excursion (TAPSE) measured by echocardiography and mortality in COVID-19: a systematic review and meta-analysis. IJID 2021; 105: 351-356.

23. Alerhand S, Hickey SM. Tricuspid annular plane systolic excursion (TAPSE) for risk stratification and prognostication of patients with pulmonary embolism. J. Emerg. Med 2020; 58(3): 449-456.

24. Ghio S, Recusani F, Klersy C, Sebastiani R, Laudisa ML, Campana C, Gavazzi A, Tavazzi L. Prognostic usefulness of the tricuspid annular plane systolic excursion in patients with congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol 2000;85:837–842

25. Juilliere Y, Barbier G, Feldmann L, et al. Additional predictive Value of both left and RVejection fractions on long term survival in idiopathic dilated cardiomyopathy. Eur Heart J. 1997; 18:276–80.

26. Anavekar NS, Gerson D, Skali H, et al. Two-dimensional assessment of RVfunction: an echocardiographic-MRI correlative study. Echocardiography. 2007; 24:452-6.

27. Raymond RJ, Hinderliter AL, Willis PW, Ralph D, Caldwell EJ, Williams W, Ettinger NA, Hill NS, Summer WR, de Boisblanc B, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002;39:1214–1219.

28. Galie N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, Espinola-Zavaleta N, Rocchi G, Manes A, Frantz R, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:1380–1386

29. Fahim O, Fawzi A, Beshay M, Yousif M. (2020). Study of the relation between speckle tracking echocardiography and BODE index in patients with chronic obstructive pulmonary disease. The Egyptian Journal of Chest Diseases and Tuberculosis 2020; 69(3): 524-531.

30. Ghosh, Indira, et al. "Echocardiographic evaluation of right ventricle in different stages of chronic obstructive pulmonary disease (COPD) and its correlation with severity of the disease." World Journal of Pharmaceutical Research 6.14 (2017): 632-643.

31.Chen J, Wu X, Su L,Gao S. Echocardiographic evaluation of right ventricular function in aged patients with chronic obstructive pulmonary disease. Chinese J. Rehabilitation Med 2019; 90-93.

14